We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

PET/CT Superior at Lesion Detection for Head and Neck Paragangliomas than Gold Standard MRI

By MedImaging International staff writers
Posted on 27 Jun 2024

Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors that present significant diagnostic and therapeutic challenges due to their complex locations. Imaging plays an essential role in managing these tumors. Although MRI is typically used for preoperative assessment and follow-up, its capacity to distinguish between residual tumors and postoperative changes like scar tissue is somewhat limited. Now, a new imaging technique, 68Ga-DOTATATE PET/CT, offers a more precise differentiation between residual or recurrent tumors and post-surgical scar tissue in patients with HNPGLs, outperforming MRI. This method provides valuable functional details about the tumors, suggesting it could be crucial in enhancing strategies for preoperative and postoperative treatment planning in HNPGL patients.

Researchers at University Hospital Cleveland Medical Center (Cleveland, OH, USA) conducted a study involving 25 patients, some with a preoperative clinical suspicion of HNPGLs (five patients) and others with postoperative pathology-confirmed HNPGLs (20 patients). These patients underwent both 68Ga-DOTATATE PET/CT and MRI scans. A nuclear medicine physician with expertise in 68Ga-DOTATATE PET/CT reviewed all images. The results showed that 68Ga-DOTATATE PET/CT was superior in detecting lesions and more accurately defining the tumor extent in HNPGL patients compared to MRI. It also excelled in distinguishing between recurrent or residual tumors and postoperative scar tissue, demonstrating higher sensitivity and specificity than MRI alone.


Image: Axial imaging of glomus jugulare and treatment planning (Photo courtesy of P. Wojtylak, University Hospitals of Cleveland)
Image: Axial imaging of glomus jugulare and treatment planning (Photo courtesy of P. Wojtylak, University Hospitals of Cleveland)

“68Ga-DOTATATE PET/CT holds promise as a reliable imaging biomarker for HNPGLs, offering enhanced sensitivity and specificity compared to conventional imaging modalities,” said Patrick Wojtylak, MSHA, CNMT, Radiology System Manager for Nuclear Medicine at University Hospital Cleveland Medical Center. “Integrating 68Ga-DOTATATE PET/CT into the clinical management of HNPGLs can lead to more accurate diagnosis, better treatment planning, and improved patient outcomes.”

Related Links:
UH Cleveland Medical Center


New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
X-ray Diagnostic System
FDX Visionary-A
New
Mobile Barrier
Tilted Mobile Leaded Barrier
Ultra-Flat DR Detector
meX+1717SCC

Latest Nuclear Medicine News

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

New Imaging Agent to Drive Step-Change for Brain Cancer Imaging

Portable PET Scanner to Detect Earliest Stages of Alzheimer’s Disease